<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00128700</url>
  </required_header>
  <id_info>
    <org_study_id>EORTC-26041-22041</org_study_id>
    <secondary_id>EORTC-26041</secondary_id>
    <secondary_id>EORTC-22041</secondary_id>
    <secondary_id>EUDRACT-2004-003896-35</secondary_id>
    <nct_id>NCT00128700</nct_id>
  </id_info>
  <brief_title>Temozolomide and Radiation Therapy With or Without Vatalanib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme</brief_title>
  <official_title>Phase I/II Study on Concomitant and Adjuvant Temozolomide and Radiotherapy With or Without PTK787/ZK222584 in Newly Diagnosed GBM</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>European Organisation for Research and Treatment of Cancer - EORTC</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>European Organisation for Research and Treatment of Cancer - EORTC</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as temozolomide, work in different ways to stop&#xD;
      the growth of tumor cells, either by killing the cells or by stopping them from dividing.&#xD;
      Radiation therapy uses high-energy x-rays to kill tumor cells. Vatalanib may stop the growth&#xD;
      of tumor cells by blocking blood flow to the tumor. Giving temozolomide and radiation therapy&#xD;
      together with vatalanib may kill more tumor cells.&#xD;
&#xD;
      PURPOSE: This randomized phase I/II trial is studying the side effects and best dose of&#xD;
      vatalanib when given together with temozolomide and radiation therapy and to see how well&#xD;
      they work in treating patients with newly diagnosed glioblastoma multiforme.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine the maximum tolerated dose and recommended phase II dose of vatalanib when&#xD;
           given in combination with temozolomide and radiotherapy in patients with newly diagnosed&#xD;
           glioblastoma multiforme. (Phase I)&#xD;
&#xD;
        -  Determine the safety and tolerability of this regimen in these patients. (Phase I)&#xD;
&#xD;
        -  Determine the 6-month progression-free survival of patients treated with&#xD;
           chemoradiotherapy comprising temozolomide and radiotherapy with or without vatalanib&#xD;
           followed by adjuvant therapy comprising temozolomide and vatalanib or temozolomide alone&#xD;
           with or without maintenance therapy comprising vatalanib alone. (Phase II)&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Determine 12-month overall survival of patients treated with these regimens. (Phase II)&#xD;
&#xD;
        -  Determine the toxicity profile of these regimens in these patients. (Phase II)&#xD;
&#xD;
        -  Correlate expression of angiogenesis and hypoxia markers and MGMT methylation status&#xD;
           with clinical outcome in patients treated with these regimens.&#xD;
&#xD;
      OUTLINE: This is a phase I, multicenter, open-label, non-randomized, dose-escalation study of&#xD;
      vatalanib followed by a phase II, randomized, controlled study. Patients enrolled in the&#xD;
      phase II portion of the study are stratified according to participating center, age (&lt; 50&#xD;
      years vs ≥ 50 years), corticosteroid intake (yes vs no), and mini-mental status evaluation&#xD;
      score (&lt; 27 vs 27-29 vs 30).&#xD;
&#xD;
        -  Phase I:&#xD;
&#xD;
             -  Chemoradiotherapy: Patients receive oral temozolomide once daily for 6-7 weeks and&#xD;
                oral vatalanib once daily for 6 weeks. Patients also undergo radiotherapy once&#xD;
                daily, 5 days a week, for 6 weeks. Four weeks after the completion of&#xD;
                chemoradiotherapy, patients proceed to adjuvant therapy. During the 4-week period&#xD;
                between chemoradiotherapy and adjuvant therapy, patients continue to receive oral&#xD;
                vatalanib twice daily.&#xD;
&#xD;
      Cohorts of 3-6 patients receive escalating doses of vatalanib during chemoradiotherapy until&#xD;
      the maximum tolerated dose is determined (MTD). The MTD is defined as the dose preceding that&#xD;
      at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. At least 6 patients are&#xD;
      treated at the MTD.&#xD;
&#xD;
        -  Adjuvant therapy: Patients receive oral temozolomide once daily on days 1-5 and oral&#xD;
           vatalanib twice daily on days 1-28. Treatment repeats every 28 days for 6 courses in the&#xD;
           absence of disease progression or unacceptable toxicity. Patients then proceed to&#xD;
           maintenance therapy.&#xD;
&#xD;
        -  Maintenance therapy: Patients continue to receive oral vatalanib twice daily in the&#xD;
           absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
             -  Phase II: Patients are randomized to 1 of 3 treatment arms.&#xD;
&#xD;
        -  Arm I:&#xD;
&#xD;
             -  Chemoradiotherapy: Patients receive oral temozolomide once daily for 6-7 weeks and&#xD;
                undergo radiotherapy once daily, 5 days a week, for 6 weeks. Four weeks after the&#xD;
                completion of chemoradiotherapy, patients proceed to adjuvant therapy.&#xD;
&#xD;
             -  Adjuvant therapy: Patients receive oral temozolomide once daily on days 1-5.&#xD;
                Treatment repeats every 28 days for up to 6 courses in the absence of disease&#xD;
                progression or unacceptable toxicity.&#xD;
&#xD;
        -  Arm II:&#xD;
&#xD;
             -  Chemoradiotherapy: Patients receive temozolomide and undergo radiotherapy as in arm&#xD;
                I. Patients also receive vatalanib twice daily for 6 weeks at the MTD determined in&#xD;
                phase I. Four weeks after the completion of chemoradiotherapy, patients proceed to&#xD;
                adjuvant therapy. During the 4-week period between chemoradiotherapy and adjuvant&#xD;
                therapy, patients continue to receive oral vatalanib twice daily.&#xD;
&#xD;
             -  Adjuvant therapy: Patients receive temozolomide and vatalanib as in phase I&#xD;
                adjuvant therapy. Patients then proceed to maintenance therapy.&#xD;
&#xD;
             -  Maintenance therapy: Patients continue to receive vatalanib as in phase I&#xD;
                maintenance therapy.&#xD;
&#xD;
        -  Arm III:&#xD;
&#xD;
             -  Chemoradiotherapy: Patients receive temozolomide and undergo radiotherapy as in arm&#xD;
                I. Four weeks after the completion of chemoradiotherapy, patients proceed to&#xD;
                adjuvant therapy. During the 4-week period between chemoradiotherapy and adjuvant&#xD;
                therapy, patients receive oral vatalanib twice daily.&#xD;
&#xD;
             -  Adjuvant therapy: Patients receive temozolomide and vatalanib as in phase I&#xD;
                adjuvant therapy. Patients then proceed to maintenance therapy.&#xD;
&#xD;
             -  Maintenance therapy: Patients continue to receive vatalanib as in phase I&#xD;
                maintenance therapy.&#xD;
&#xD;
      After completion of study treatment, patients are followed every 3 months for survival.&#xD;
&#xD;
      PROJECTED ACCRUAL: Approximately 3-18 patients will be accrued for the phase I portion of&#xD;
      this study. A total of 201 patients (67 per treatment arm) will be accrued for the phase II&#xD;
      portion of this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2005</start_date>
  <primary_completion_date type="Actual">November 2007</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose-limiting toxicity and maximum tolerated dose of vatalanib as determined by CTCAE v3.0 during phase I</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Progression-free survival at 6 months during phase II</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Severe toxic events as assessed by CTCAE v3.0 at weeks 3 and 6 (concomitant treatment), weeks 2 and 4 after radiotherapy, before each course of adjuvant treatment, monthly during maintenance treatment, and every 3 months during follow-up in phase II</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival at 1 year during phase II</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation of angiogenesis and hypoxia markers expression and O-6-methylguanine DNA methyltransferase (MGMT) methylation status with clinical outcome during phase II</measure>
  </secondary_outcome>
  <enrollment type="Actual">20</enrollment>
  <condition>Brain and Central Nervous System Tumors</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>temozolomide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vatalanib</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>adjuvant therapy</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiation therapy</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed glioblastoma multiforme&#xD;
&#xD;
               -  Newly diagnosed disease&#xD;
&#xD;
          -  Deemed to be amenable to concurrent and adjuvant temozolomide treatment by the&#xD;
             principal investigator&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  18 to 69&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  ECOG 0-1&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  Absolute neutrophil count ≥ 1,500/mm^3&#xD;
&#xD;
          -  Platelet count ≥ 100,000/mm^3&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Bilirubin &lt; 1.5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  Alkaline phosphatase &lt; 2.5 times ULN&#xD;
&#xD;
          -  ALT and AST &lt; 2.5 times ULN&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine ≤ 1.7 mg/dL&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
          -  Cardiac function clinically normal&#xD;
&#xD;
          -  12-lead ECG normal&#xD;
&#xD;
          -  No ischemic heart disease within the past 6 months&#xD;
&#xD;
          -  No uncontrolled cardiac arrhythmia&#xD;
&#xD;
          -  No uncontrolled hypertension&#xD;
&#xD;
          -  No history of stroke&#xD;
&#xD;
          -  No history of congenital long QT syndrome&#xD;
&#xD;
          -  QTc interval ≤ 450 msec for males or ≤ 470 msec for females by 12-lead ECG&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No other malignancy except adequately treated basal cell or squamous cell skin cancer&#xD;
             or cone biopsied carcinoma in situ of the cervix&#xD;
&#xD;
          -  No active uncontrolled infection&#xD;
&#xD;
          -  No other unstable systemic disease&#xD;
&#xD;
          -  No psychological, familial, sociological, or geographical condition that would&#xD;
             preclude study compliance or follow-up schedule&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  No prior anti-vascular endothelial growth factor therapy&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  No prior chemotherapy&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  Concurrent corticosteroids allowed provided the patient is on stable or decreasing&#xD;
             doses for ≥ 2 weeks before study entry&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  No prior radiotherapy&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  More than 8 days, but &lt; 6 weeks, since prior surgery or biopsy&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  No prior randomization on this study&#xD;
&#xD;
          -  No concurrent warfarin, warfarin-derived drugs, or similar anticoagulants&#xD;
&#xD;
          -  No other concurrent anticancer therapy&#xD;
&#xD;
          -  No other concurrent investigational agents&#xD;
&#xD;
          -  No concurrent enzyme inducing antiepileptic drugs, including any of the following:&#xD;
&#xD;
               -  Carbamazepine&#xD;
&#xD;
               -  Fosphenytoin&#xD;
&#xD;
               -  Oxcarbazepine&#xD;
&#xD;
               -  Phenobarbital&#xD;
&#xD;
               -  Phenytoin&#xD;
&#xD;
               -  Primidone&#xD;
&#xD;
          -  No concurrent grapefruit or grapefruit juice&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>69 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alba A. Brandes, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Azienda Ospedaliera di Padova</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>U.Z. Gasthuisberg</name>
      <address>
        <city>Leuven</city>
        <zip>B-3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum der Universitaet Regensburg</name>
      <address>
        <city>Regensburg</city>
        <zip>D-93053</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera di Padova</name>
      <address>
        <city>Padova</city>
        <zip>35128</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Daniel Den Hoed Cancer Center at Erasmus Medical Center</name>
      <address>
        <city>Rotterdam</city>
        <zip>3075 EA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire Vaudois</name>
      <address>
        <city>Lausanne</city>
        <zip>CH-1011</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Switzerland</country>
  </location_countries>
  <results_reference>
    <citation>Brandes AA, Stupp R, Hau P, Lacombe D, Gorlia T, Tosoni A, Mirimanoff RO, Kros JM, van den Bent MJ. EORTC study 26041-22041: phase I/II study on concomitant and adjuvant temozolomide (TMZ) and radiotherapy (RT) with PTK787/ZK222584 (PTK/ZK) in newly diagnosed glioblastoma. Eur J Cancer. 2010 Jan;46(2):348-54. doi: 10.1016/j.ejca.2009.10.029. Epub 2009 Nov 27.</citation>
    <PMID>19945857</PMID>
  </results_reference>
  <verification_date>September 2012</verification_date>
  <study_first_submitted>August 8, 2005</study_first_submitted>
  <study_first_submitted_qc>August 8, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 10, 2005</study_first_posted>
  <last_update_submitted>September 20, 2012</last_update_submitted>
  <last_update_submitted_qc>September 20, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 24, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>adult glioblastoma</keyword>
  <keyword>adult giant cell glioblastoma</keyword>
  <keyword>adult gliosarcoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioblastoma</mesh_term>
    <mesh_term>Nervous System Neoplasms</mesh_term>
    <mesh_term>Central Nervous System Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Temozolomide</mesh_term>
    <mesh_term>Vatalanib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

